Software Industry: Nexway™ Reinforces the Customer Experience Capabilities of its Monetize Personalized Growth Platform
26.1.2021 16:00:00 EET | Business Wire | Press release
Nexway, a leading software and service company for e-commerce and payments, is very excited to launch the latest features on its personalized growth platform Nexway Monetize, moving forward in its mission to expand the online footprint and sales potential of software vendors, games publishers and service providers across 140 countries around the world.
In today’s uncertain business environment, the e-commerce and payment leader is looking to leverage its best technologies to offer a seamless purchase experience, helping its clients to remain flexible in their strategic approach to e-commerce.
Nexway‘s teams are driving versatility, flexibility, and frictionless features to conquer new markets and expand into vertical sectors linked to customer monetization, subscriptions, and B2B sales management. Nexway also intends to continue growing thanks to its agility, expertise, and high level of the customer purchase experience.
"Customer experience is a constantly moving target, changing to meet customer needs, expectations, and evolution. Every customer has different needs and flexibility skills are crucial to adjust to situations and being able to effectively address such challenges. Being flexible with your customers is a top priority in the COVID-19 world." comments Frédéric Ribau, Chief Technical Officer and Chief Product Officer at Nexway.
To meet these expectations and context, the Company has tuned its Nexway Monetize platform with new e-commerce features and payment capabilities.
NEXWAY MONETIZE NEW FEATURES RELEASED
1/ Nexway launches multiple pre-order options available right away on the Monetize platform. This feature is mostly aimed, but not limited, at gaming publishers, allowing to convert consumers before a product/game release, to create buzz, to offer exclusivity or bonuses to its community, or simply to test its product/game. Read more.
2/ Nexway announces the evolution of its subscription capabilities and launches its subscription trial extension. This feature is intended for digital product and service providers to offer consumers a subscription with a trial period, to be renewed and extended automatically into a standard paying subscription. The trial period will be a new period integrated into the subscription model, allowing the provider to define the duration of the trial period and switch it on or off depending on his will. Read more.
3/ Nexway expands its global payment services, announcing a massive regional expansion of its payment capabilities and services. Efficiently selling in different countries requires expertise and specific capabilities. Nexway Monetize simplifies commerce with powerful payment technology and helps its customers to process payments in local currencies with the most adapted payment methods worldwide.
- Monetize supports India and the Nordics countries with local currencies and regional preferred payment methods
- In addition to Brazil, Nexway reinforces its LATAM footprint
- A range of new currencies has been implemented on Nexway’s payment platform
- Payments in installments
are now available in Brazil
- Nexway enables its clients to provide local offline payment methods
4/ To help publishers to develop their reseller network and bring differentiation to its existing reseller portal offer, Nexway has developed automatic commissions on license renewals feature for resellers. The goal of this feature is to increase the loyalty of the resellers. Read more.
“Whether B2B or B2C, today’s customers have an ever-higher expectation of service. Our challenge is to optimize the experience of our customers and support them in creating a strong differentiation and competitive advantage within the digital economy. Throughout 2021, we plan to add new solutions and features to support commerce by allowing companies to expand across borders and verticals,” adds Frédéric Ribau.
Product Documentation: Nexway Monetize
Ready to enhance customer experience and boost your global sales potential! Discover Nexway Monetize: personalized e-commerce growth platform. GET STARTED NOW
ABOUT NEXWAY
Nexway SASU is a leading e-commerce and payment player. Combining technology and managed services, Nexway helps online businesses scale, grow, and thrive. Nexway’s expertise in subscriptions, local payments, fraud prevention, and reseller management enables customers to transform their purchasing experience and accelerate sales. Founded in 2002 and headquartered in Paris–La Défense, France, Nexway has subsidiaries in the USA, Brazil, Italy, Spain, Poland, and Japan. Companies that rely on Nexway include FNAC-Darty™, Amazon™, Kaspersky™, Adobe™, Avast™, TakeTwo™, and hundreds more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210126005053/en/
Contact information
Media
Cécile Abescat
cabescat@nexway.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom